Claims for Patent: 9,493,738

Summary for Patent: 9,493,738

Title:	Method for producing high yield attenuated Salmonella strains
Abstract:	This invention relates to a novel method for growing attenuated mutant Salmonella typhi strains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing said Salmonella typhi strain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutant Salmonella typhi strains obtainable by said method and to an attenuated mutant Salmonella typhi strain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.
Inventor(s):	Lubenau; Heinz (Neustadt an der Weinstrasse, DE), Siede; Holger (Ronnenberg, DE), Janssen; Renate (Hannover, DE), Springer; Marco (Wendlingen, DE)
Assignee:	VAXIMM AG (Basel, CH)
Application Number:	14/366,186
Patent Claims:	1. A method for growing an attenuated mutant strain of Salmonella typhi lacking galactose epimerase activity and comprising at least one copy of a recombinant DNA molecule comprising a eukaryotic expression cassette, comprising the step of culturing the strain in a buffered medium comprising peptone at approximately neutral starting pH value at fermentation scale, wherein no glucose is added to the medium during the fermentation, wherein the amount of glucose in the medium during the fermentation is adjusted such that the amount of glucose is reduced to zero before reaching the stationary phase, and wherein the volume of the medium is at least about 10 l. 2. The method of claim 1, wherein said attenuated mutant strain of Salmonella typhi is Salmonella typhi Ty21a. 3. The method of claim 1, wherein the expression cassette encodes a vascular endothelial growth factor (VEGF) receptor protein selected from the group consisting of human vascular endothelial growth factor receptor-2 (VEGFR-2) having the amino acid sequence as found in SEQ ID NO 1 and a homolog thereof that shares at least about 80% homology therewith. 4. The method of claim 1, wherein the buffered medium comprises peptone of non-animal origin. 5. The method of claim 1, wherein the volume of the medium is from about 10 l to about 10,000 l, or from about 30 l to about 1,000 l, or from about 100 l to about 500 l. 6. The method of claim 1, wherein the starting glucose concentration is from about 0 g/l to about 4 g/l. 7. The method of claim 1, wherein the starting pH value is from about 6 to about 8, or from about 6.5 to about 7.5. 8. The method of claim 1, wherein the pH value is adjusted during said culturing to a pH value of about 6 to about 8, or to a pH value of about 6.5 to about 7.5. 9. The method of claim 1, wherein the progress of growth is determined by (i) measuring the optical density (OD), or by (ii) measuring the cell density, or by (iii) measuring the colony forming units (CFU) value by taking samples and plating on agar plates. 10. The method of claim 1, wherein the cells are harvested before reaching an optical density of about 6, when measured at a wavelength of 600 nm. 11. The method of claim 1, wherein the attenuated mutant strain of Salmonella typhi is Salmonella typhi Ty21a and the recombinant DNA molecule comprises a kanamycin resistance gene, a pMB1 origin of replication (ori), and a eukaryotic expression cassette encoding human VEGFR-2, under the control of the cytomegalovirus (CMV) promoter. 12. The method of claim 4, wherein the buffered medium is Tryptic Soy Broth (TSB) of non-animal origin. 13. The method of claim 1 or claim 9, wherein the progress of growth is determined by (i) measuring the optical density (OD) by (ia) in-situ monitoring of the optical density of the culture or by (ib) taking samples and measuring the optical density of the samples, or by (ii) measuring the cell density (iia) microscopically or (iib) by measuring the electrical resistance, or (iic) by flow cytometry, or by (iii) measuring the colony forming units (CFU) value by taking samples and plating on agar plates. 14. The method of claim 1, wherein the cells are harvested at an optical density of about 6, when measured at a wavelength of 600 nm. 15. The method of claim 11, wherein human VEGFR-2 has the nucleic acid sequence as found in SEQ ID NO 2.

Details for Patent 9,493,738

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Travel Health, Inc.	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	12/15/1989		2031-12-22